Clinical Trials match your criteria
-
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
A Phase II study of Naxitamab added to induction Therapy for Subjects with Newly Diagnosed High Risk Neuroblastoma
-
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
-
A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis
A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis
-
Longitudinal evaluation of Myoelectric Prosthetic Devices in Children with Upper Congenital Limb Deficiency
Longitudinal evaluation of Myoelectric Prosthetic Devices in Children with Upper Congenital Limb Deficiency
-
Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
-
Development and Validation of a Computational Fluid Dynamic Model of Dextro-transposition of the Great Arteries
Development and Validation of a Computational Fluid Dynamic Model of Dextro-transposition of the Great Arteries
-
Randomized, double-blind study comparing frexalimab (SAR441344) to teriflunomide in adult with relapsing multiple sclerosis
Master protocol of two independent, randomized, double-blind Phase 3 studies comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
-
A Study of the Genetic Determinants of Response to Growth Hormone Treatment in Children with Idiopathic Short Stature
A Study of the Genetic Determinants of Response to Growth Hormone Treatment in Children with Idiopathic Short Stature
-
A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease
A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease
